FIGURE 1.
Overall tumor response in Japanese patients with gastric cancer treated with (A) first‐line pembrolizumab with S‐1 + oxaliplatin (cohort 1) or (B) first‐line pembrolizumab with S‐1 + cisplatin (cohort 2), assessed by central review according to RECIST version 1.1. Best change from baseline in the sum of the longest target lesion diameter per patient by programmed cell death‐ligand 1 expression. CPS, combined positive score